MedKoo Cat#: 124469 | Name: Fosgonimeton sodium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fosgonimeton is a Novel Positive Modulator of the HGF/MET System, Fosgonimeton Promotes Neurotrophic and Procognitive Effects in Models of Dementia. Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease. In vivo, fosgonimeton administration led to functional improvement in an intracerebroventricular Aβ25-35 rat model of AD, as it significantly rescued cognitive function in the passive avoidance test.

Chemical Structure

Fosgonimeton sodium
Fosgonimeton sodium
CAS#2091773-96-3 (sodium)

Theoretical Analysis

MedKoo Cat#: 124469

Name: Fosgonimeton sodium

CAS#: 2091773-96-3 (sodium)

Chemical Formula: C27H44N4NaO8P

Exact Mass: 606.2800

Molecular Weight: 606.63

Elemental Analysis: C, 53.46; H, 7.31; N, 9.24; Na, 3.79; O, 21.10; P, 5.11

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Synonym
Fosgonimeton sodium; ATH1017; TH-1017; TH 1017; NDX1017; NDX 1017; NDX-1017;
IUPAC/Chemical Name
sodium;[4-[(2S)-3-[[(2S,3S)-1-[(6-amino-6-oxohexyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-2-(hexanoylamino)-3-oxopropyl]phenyl] hydrogen phosphate
InChi Key
FKDVTTURUVVCAT-HEGDDJOISA-M
InChi Code
InChI=1S/C27H45N4O8P.Na/c1-4-6-8-12-24(33)30-22(18-20-13-15-21(16-14-20)39-40(36,37)38)26(34)31-25(19(3)5-2)27(35)29-17-10-7-9-11-23(28)32;/h13-16,19,22,25H,4-12,17-18H2,1-3H3,(H2,28,32)(H,29,35)(H,30,33)(H,31,34)(H2,36,37,38);/q;+1/p-1/t19-,22-,25-;/m0./s1
SMILES Code
CCCCCC(=O)N[C@@H](CC1=CC=C(C=C1)OP(=O)(O)[O-])C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCCCCCC(=O)N.[Na+]
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 606.63 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Reda SM, Setti SE, Berthiaume AA, Wu W, Taylor RW, Johnston JL, Stein LR, Moebius HJ, Church KJ. Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease. Neurotherapeutics. 2024 Apr 9;21(4):e00350. doi: 10.1016/j.neurot.2024.e00350. Epub ahead of print. PMID: 38599894. 2: Khan SA, Khan S, Kausar H, Shah R, Luitel A, Gautam S, Parajuli SB, Rauniyar VK, Khan MAB. Insights into the management of Lewy body dementia: a scoping review. Ann Med Surg (Lond). 2024 Jan 3;86(2):930-942. doi: 10.1097/MS9.0000000000001664. PMID: 38333295; PMCID: PMC10849442. 3: Degirmenci Y, Angelopoulou E, Georgakopoulou VE, Bougea A. Cognitive Impairment in Parkinson's Disease: An Updated Overview Focusing on Emerging Pharmaceutical Treatment Approaches. Medicina (Kaunas). 2023 Oct 1;59(10):1756. doi: 10.3390/medicina59101756. PMID: 37893474; PMCID: PMC10608778. 4: Skylar-Scott IA, Sha SJ. Lewy Body Dementia: An Overview of Promising Therapeutics. Curr Neurol Neurosci Rep. 2023 Oct;23(10):581-592. doi: 10.1007/s11910-023-01292-0. Epub 2023 Aug 12. PMID: 37572228. 5: Johnston JL, Reda SM, Setti SE, Taylor RW, Berthiaume AA, Walker WE, Wu W, Moebius HJ, Church KJ. Fosgonimeton, a Novel Positive Modulator of the HGF/MET System, Promotes Neurotrophic and Procognitive Effects in Models of Dementia. Neurotherapeutics. 2023 Mar;20(2):431-451. doi: 10.1007/s13311-022-01325-5. Epub 2022 Dec 20. PMID: 36538176; PMCID: PMC10121968. 6: Hua X, Church K, Walker W, L'Hostis P, Viardot G, Danjou P, Hendrix S, Moebius HJ. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial. J Alzheimers Dis. 2022;86(3):1399-1413. doi: 10.3233/JAD-215511. PMID: 35180125; PMCID: PMC9108585.